Skip to content

Search

The second rheumatic heart disease forum report

Building on the foundation of the first RHD forum, over 150 interested participants met to discuss critical issues on the RHD landscape.

Development of an opsonophagocytic killing assay for group a streptococcus

This Group A Streptococcus OPKA assay has the potential to provide a robust and reproducible platform to accelerate GAS vaccine development.

Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD)

The current prophylactic treatment to prevent rheumatic heart disease requires four-weekly intramuscular injection of a suspension of the poorly soluble benzathine salt form of penicillin G (BPG) often for more than 10 years. In seeking to reduce the frequency of administration to improve adherence, biodegradable polymer matrices have been investigated.

Utility of auscultatory screening for detecting rheumatic heart disease in high-risk children in Australia's Northern Territory

Sensitivity and positive predictive value of cardiac auscultation compared with echocardiography is poor, regardless of the expertise of the auscultator.

Acute rheumatic fever and rheumatic heart disease: Incidence and progression in the Northern Territory of Australia 1997 to 2010

The reduction in ARF recurrence indicates that the RHD control program has improved secondary prophylaxis; a decline in RHD incidence is expected to follow.

Scabies and impetigo in Timor-Leste: A school screening study in two districts

Scabies and impetigo are common in Timor-Leste, with very high prevalence of scabies in the rural district of Ermera

Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study

Group A Streptococcus (GAS) M protein is an important virulence factor and potential vaccine antigen, and constitutes the basis for strain typing (emm-typing).

Group A streptococcal vaccines: Paving a path for accelerated development

Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.

Calculation of the age of the first infection for skin sores and scabies in five remote communities in northern Australia

Prevalence of skin sores and scabies in remote Australian Aboriginal communities remains unacceptably high, with Group A Streptococcus (GAS) the dominant pathogen. We aim to better understand the drivers of GAS transmission using mathematical models.

Progress toward a global Group A streptococcal vaccine

The desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart disease.

Rheumatic heart disease in Timor-Leste school students: an echocardiography-based prevalence study

The rates of RHD in Timor-Leste are among the highest in the world, and prevalence is higher among girls than boys. Community engagement is essential for ensuring follow-up and the effective delivery of secondary prophylaxis.

The Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (2nd edition)

Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) occur at very high rates among Aboriginal and Torres Strait Islander people.

The NICE-GUT trial protocol: A randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal children

Diarrhoeal disease is the second leading cause of death in children under 5 years globally, killing 525 000 annually. Australian Aboriginal and Torres Strait Islander (hereafter Aboriginal) children suffer a high burden of disease.

Preventing urinary tract infections in early childhood

Urinary tract infection (UTI) is common in children, causes them considerable discomfort, as well as distress to parents and has a tendency to recur.

Rheumatic heart disease: infectious disease origin, chronic care approach.

Rheumatic heart disease (RHD) is a chronic cardiac condition with an infectious aetiology, causing high disease burden in low-income settings.

The rationale for action to end new cases of rheumatic heart disease in Australia

The choice of RHD is telling: the disease is a marker of inequality, a novel lens for considering health systems and a feasible target for disease control.

Global, regional, & national burden of rheumatic heart disease, 1990-2015

We estimated the global disease prevalence of and mortality due to rheumatic heart disease over a 25-year period

Clinical outcomes for young people with screening-detected and clinically-diagnosed rheumatic heart disease in Fiji

Young people with screening-detected RHD have worse health outcomes than screen-negative cases in Fiji.